Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
EBioMedicine ; 83: 104204, 2022 Sep.
Article in English | MEDLINE | ID: mdl-35952494

ABSTRACT

BACKGROUND: Multiple sclerosis is characterised by inflammation, oligodendrocyte loss and axonal demyelination and shows an additional impact on astrocytes, and their polarization. Although a certain degree of spontaneous myelin repair can be observed, disease progression, and aging impair regeneration efforts highlighting the need to better understand glial cell dynamics to establish specific regenerative treatments. METHODS: Applying a chronic demyelination model, we here analysed demyelination and remyelination related effects on astrocytes and stem cell niches and studied the consequences of medrysone application on myelin repair, and astrocyte polarization. FINDINGS: Medrysone induced recovery of mature oligodendrocytes, myelin expression and node formation. In addition, C3d/S100a10 co-expression in astrocytes was enhanced. Moreover, Timp1 expression in C3d positive astrocytes revealed another astrocytic phenotype with a myelination promoting character. INTERPRETATION: Based on these findings, specific astrocyte subpopulations are suggested to act in a myelin regenerative way and manner the regulation of which can be positively modulated by this corticosteroid. FUNDING: This work was supported by the Jürgen Manchot Stiftung, the Research Commission of the medical faculty of the Heinrich-Heine-University of Düsseldorf, the Christiane and Claudia Hempel Foundation for clinical stem cell research and the James and Elisabeth Cloppenburg, Peek and Cloppenburg Düsseldorf Stiftung.


Subject(s)
Demyelinating Diseases , Myelin Sheath , Adrenal Cortex Hormones , Animals , Astrocytes/metabolism , Cuprizone/metabolism , Cuprizone/pharmacology , Demyelinating Diseases/metabolism , Disease Models, Animal , Mice , Mice, Inbred C57BL , Myelin Sheath/metabolism , Oligodendroglia/metabolism , Pregnenediones
2.
Cells ; 11(5)2022 02 25.
Article in English | MEDLINE | ID: mdl-35269426

ABSTRACT

Nijmegen Breakage Syndrome (NBS) is a rare autosomal recessive genetic disorder caused by mutations within nibrin (NBN), a DNA damage repair protein. Hallmarks of NBS include chromosomal instability and clinical manifestations such as growth retardation, immunodeficiency, and progressive microcephaly. We employed induced pluripotent stem cell-derived cerebral organoids from two NBS patients to study the etiology of microcephaly. We show that NBS organoids carrying the homozygous 657del5 NBN mutation are significantly smaller with disrupted cyto-architecture. The organoids exhibit premature differentiation, and Neuronatin (NNAT) over-expression. Furthermore, pathways related to DNA damage response and cell cycle are differentially regulated compared to controls. After exposure to bleomycin, NBS organoids undergo delayed p53-mediated DNA damage response and aberrant trans-synaptic signaling, which ultimately leads to neuronal apoptosis. Our data provide insights into how mutations within NBN alters neurogenesis in NBS patients, thus providing a proof of concept that cerebral organoids are a valuable tool for studying DNA damage-related disorders.


Subject(s)
Microcephaly , Nijmegen Breakage Syndrome , DNA Damage , Humans , Microcephaly/genetics , Nijmegen Breakage Syndrome/genetics , Nijmegen Breakage Syndrome/metabolism , Organoids/metabolism , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism
3.
Naunyn Schmiedebergs Arch Pharmacol ; 393(10): 1921-1930, 2020 10.
Article in English | MEDLINE | ID: mdl-32444988

ABSTRACT

Traumatic brain injury (TBI) is a critical health problem worldwide, with a high incidence rate and potentially severe long-term consequences. Depending on the level of mechanical stress, astrocytes react with complex morphological and functional changes known as reactive astrogliosis. In cases of severe tissue injury, astrocytes proliferate in the area immediately adjacent to the lesion to form the glial scar, which is a major barrier to neuronal regeneration in the central nervous system. The flavonoid agathisflavone has been shown to have neuroprotective, neurogenic, and immunomodulatory effects and could have beneficial effects in situations of TBI. In this study, we investigated the effects of agathisflavone on modulating the responses of astrocytes and neurons to injury, using the in vitro scratch wound model of TBI in primary cultures of rat cerebral cortex. In control conditions, the scratch wound induced an astroglial injury response, characterized by upregulation of glial fibrillary acidic protein (GFAP) and hypertrophy, together with the reduction in proportion of neurons within the lesion site. Treatment with agathisflavone (1 µM) decreased astroglial GFAP expression and hypertrophy and induced an increase in the number of neurons and neurite outgrowth into the lesion site. Agathisflavone also induced increased expression of the neurotrophic factors NGF and GDNF, which are associated with the neuroprotective profile of glial cells. These results demonstrate that in an in vitro model of TBI, the flavonoid agathisflavone modulates the astrocytic injury response and glial scar formation, stimulating neural recomposition.


Subject(s)
Astrocytes/drug effects , Biflavonoids/pharmacology , Biflavonoids/therapeutic use , Brain Injuries, Traumatic/drug therapy , Neurons/drug effects , Animals , Astrocytes/physiology , Brain Injuries, Traumatic/pathology , Cells, Cultured , Dose-Response Relationship, Drug , Female , Mice , Neurons/physiology , Pregnancy , Rats , Rats, Wistar
4.
Int Immunopharmacol ; 70: 302-312, 2019 May.
Article in English | MEDLINE | ID: mdl-30852286

ABSTRACT

In the central nervous system (CNS), neuroinflammation, especially that modulated by the cell response of astrocytes and microglia, is associated with damage to neurons in neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and, Multiple Sclerosis. Lupeol is a dietary triterpene that has demonstrated biological activities as antioxidant. This study investigated the anti-inflammatory and neuroprotective effects of lupeol in an in vitro model of neuroinflammation in primary cerebellar cultures. Cultures were obtained from 6-day-old Wistar rats, subjected to inflammatory damage with lipopolysaccharide (LPS, 1 µg/mL) and treated with lupeol (0.1 µM). We observed, after a 48-hour treatment, through Fluorjade-B staining and immunocytochemistry (ICQ) for ßIII-tubulin, that lupeol induced neuroprotection in cultures submitted to inflammatory damage. On the other hand, through ICQ for GFAP, it was possible to observe that lupeol modulated the astrocyte morphology for Bergmann glia-like phenotype and, especially for velate astrocyte-like phenotype, both phenotypes associated with the neuroprotective profile. Moreover, RT-qPCR analysis showed that lupeol induced the down-regulation of the mRNA expression for proinflammatory markers TNF, iNOS and NLRP3, as well as the production of nitric oxide (method of Greiss), which were up-regulated by LPS, and also induced up-regulation of the mRNA expression for arginase and IL-6 mRNA. In addition, lupeol induced up-regulation of mRNA expression for neurotrophins GDNF and NGF and also for the sonic hedgehog-Gli pathway. Together, these results lead to the conclusion that lupeol inhibits neuroinflammation in cerebellar cultures and induces neuroprotection associated with the modulation of astrocyte response and expression of neurotrophic and inflammatory factors.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Astrocytes/physiology , Cerebellum/pathology , Neurogenic Inflammation/drug therapy , Pentacyclic Triterpenes/pharmacology , Animals , Astrocytes/drug effects , Cells, Cultured , Disease Models, Animal , Gene Expression Regulation , Humans , Inflammation Mediators/metabolism , Interleukin-6/genetics , Interleukin-6/metabolism , Lipopolysaccharides/immunology , NLR Family, Pyrin Domain-Containing 3 Protein/metabolism , Nerve Growth Factors/metabolism , Neurogenic Inflammation/immunology , Neuroprotection , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism , Rats , Rats, Wistar , Tubulin/metabolism , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
5.
J Pharm Pharm Sci ; 21(1): 376-385, 2018.
Article in English | MEDLINE | ID: mdl-30342562

ABSTRACT

PURPOSE: Flavonoids are a group of secondary metabolites of the polyphenols class present in several plant species. Among them, the biflavonoid agathisflavone is of interest since it bears several biological effects that include: antiviral, antitumoral, antiprotozoal and neurogenic actions. In this sense, this study aims to use the important tool of scientific prospecting to assess the level of research development concerning the flavonoid agathisflavone. METHODS: The experimental design was carried out through strategic reach with keywords on the PubMed (National Center for Biotechnology Information - NCBI) and Science Direct platforms. The articles were compiled and exported to Microsoft Office Excel 2007, where they were analyzed, stored and distributed in charts organized as to different countries, year of publication of scientific articles and journals RESULTS: The prospective research resulted in the identification of 81 scientific productions, published in several journals, submitted by different countries, in several areas of medical domain and in different years of publication over the last 50 years (1965 - 2018). It was also possible to investigate the advances in the study of agathisflavone for the development of new therapeutics. CONCLUSION: Although agathisflavone has been known in the literature since at least 1969, only 23 of the eligible articles found evaluated its possible therapeutic effects. The demonstrated biological activities of agathisflavone range from antiprotozoal to neurogenesis and neuroprotection, however, the molecule needs to be better studied at the in vivo and human level.


Subject(s)
Anti-Infective Agents/pharmacology , Antineoplastic Agents/pharmacology , Antiprotozoal Agents/pharmacology , Biflavonoids/pharmacology , Neuroprotective Agents/pharmacology , Anti-Infective Agents/chemical synthesis , Anti-Infective Agents/chemistry , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Antiprotozoal Agents/chemical synthesis , Antiprotozoal Agents/chemistry , Biflavonoids/chemical synthesis , Biflavonoids/chemistry , Drug Design , Humans , Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/chemistry , Prospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...